Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial

Conclusions: Supraorbital transcutaneous stimulation with the device used in this trial is effective and safe as a preventive therapy for migraine. The therapeutic gain (26%) is within the range of those reported for other preventive drug and nondrug antimigraine treatments. Classification of evidence: This study provides Class III evidence that treatment with a supraorbital transcutaneous stimulator is effective and safe as a preventive therapy for migraine.

http://www.neurology.org/cgi/content/short/80/8/697?rss=1

Source: Neurology - February 18, 2013 Category: Neurology Authors: Schoenen, J., Vandersmissen, B., Jeangette, S., Herroelen, L., Vandenheede, M., Gerard, P., Magis, D. Tags: All Headache, Migraine, Clinical trials Randomized controlled (CONSORT agreement), Class III ARTICLE Source Type: research